All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
Multiple myeloma (MM) accounts for 10% of all hematologic malignancies.1 The overall survival (OS) of patients with MM has improved in recent years due to the availability of several therapies, such as monoclonal antibodies, cellular therapies, immunomodulators, and autologous stem cell transplantation. However, these therapies have related side effects, such as risk of anemia, bone lesions, hypercalcemia, infection, and renal failure, which causes fatigue, cognitive impairment, and depression. Despite improved treatment, MM is incurable and progressive, and often combined with durations of remission with minimal or maintenance therapy. Given the prospect of ongoing treatment-related complications, MM is associated with a significant decline in quality of life (QoL), highlighting the need for developing supportive care that addresses the long-term side effects of MM. Supportive care can help to improve QoL and maximize functional status as patients with MM live longer with the chronic burden of treatment-related complications.1
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Maaike de Ruijter1 presented on how patients with MM can be provided supportive care to improve their QoL. Here, we summarize an overview of the presentation, including the key supportive care measures for patients with MM.
Patients with MM can experience either disease- or treatment-related symptoms (Figure 1), causing patients to be distressed. The National Comprehensive Cancer Network (NCCN) defines distress as “a multifactorial, unpleasant, emotional experience of a psychological, social and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment.”
Distress may cause patients to skip medication doses and reduce treatment efficacy, leading to poor treatment adherence, increased anxiety and depression, cause impaired cognitive function, and social isolation. Distress may make it difficult for patients to cope with cancer, and therefore, it is important to reassure patients that distress is normal during cancer. It is also essential to consider that distress symptoms may differ between patients and change over time; therefore, repeatedly asking patients about their symptoms is valuable. The NCCN Distress Thermometer and Problem List can be used to measure distress on a scale of 0 to 10.
Figure 1. Multiple myeloma disease- and treatment-related symptoms*
*Adapted from de Ruijter, et al.1
Fatigue is caused by pain, anemia, renal dysfunction, depression, and medication leading to reduced activity and insomnia in patients. The severity of fatigue will depend on the age of the patient and should be discussed with the patient, including offering tips on managing fatigue and screening tools.
Fatigue can be measured using the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) scale. This is a 40-item measure scale that assesses self-reported fatigue and its impact on daily activities and function. The FACIT-F scale includes the following domains and is available in several languages:
A FACIT-F assessment should be followed by the following:
Patients experiencing fatigue should be offered stimulating exercises, physical therapy and dietician referral, and tips for improving sleep.
The following indications should be observed in patients to check for signs of depression:
Patients experiencing depression can be supported by lowering their dexamethasone/prednisolone dose, by understanding the difference between fatigue and depression, and by talking and listening to the patient and their caregivers or family.
The following indications should be observed in patients to check for signs of cognitive impairment:
The assessment of cognitive impairment should include checking for anemia, hypothyroidism, electrolyte imbalance, B12 deficiency, severe fatigue, sleeping problems, feelings of sadness or fear, and chemo brain due to chemotherapy.
The following scales can be used to measure cognitive functioning:
Awareness amongst nurses of cognitive impairment in patients with MM is important. These patients may have difficulty remembering medication schedules or following multiple-step instructions and may not know what to do if they experience treatment-related side effects.
Medications for impaired cognitive function such as methylphenidate, amphetamine/dextroamphetamine, and memantine are not very effective and have side effects. Other treatment options are currently being investigated. Cognitive skills training may sometimes be helpful to the patients. It is important to talk to patients about cognitive impairment, measure it, identify the impact on family and caregivers, and assess if an intervention is needed. Mindfulness, a type of meditation that involves breathing methods, guided imagery, and other practices to relax the body and mind, may be a helpful option. Mindfulness may help to reduce feelings of anxiety and improve QoL and concentration.
Patients should be given the following advice to cope with impaired cognitive impairment:
SurvivorSHINE is a web-based lifestyle intervention for people living with cancer and is based on the American Cancer Society Diet and Physical Activity Guidelines and supported by evidence from three randomized controlled trials. SurvivorSHINE offers patients personalized information and tools to maintain a healthy weight through healthy eating and exercise.
This article provides an overview of how patients with MM can be supported to cope with fatigue, depression, and cognitive impairment. It highlights the importance of asking patients and their caregivers about the impact on QoL of the patient, reassuring patients that distress is common during cancer, repeatedly asking patients about their symptoms throughout the disease, and signposting patients and caregivers to help and support.
Management of pain: Understanding the current needs of patients with multiple myeloma
Although pain management is an integral part of cancer care, it is often undertreated, or the treatment is not proportional to pain intensity. Reasons for...
What supportive care is needed for patients receiving CAR T-cell therapy?
During the 4th European CAR T-cell Meeting, the MM Hub was pleased to speak with Natacha Bolaños, Lymphoma Coalition, Madrid, ES. We asked, What supportive care is needed for...
Geriatric hematology in low-resource settings: Improving care for older people through the implementation of geriatric hematology programs
Currently, more than half of the 700 million people aged 65 years or older live in low- and middle-income...
Subscribe to get the best content related to multiple myeloma delivered to your inbox